HKEX Insider Activity — 2026-09-29

by hk-insider-activities-daily

🇭🇰 HKEX DI Report — 2026-09-29

🆕 NEW ENTRY — 522 ASMPT ← BlackRock, 5.02% (increased by 0.10pp from prior filing) Read: A related BlackRock entity's stake lapsed but the group's aggregate position ticked back over 5% — a structural reshuffle, not fresh buying.

🆕 NEW ENTRY — 2402 Beijing SinoHytec ← Barclays PLC, bought 673,750 shares @ HKD10.67 for HK$7.19M total Read: Barclays crosses the 5% threshold in this H-share hydrogen fuel-cell maker, a fresh institutional stake worth tracking for follow-on flows.

🆕 NEW ENTRY — 895 Dongjiang Environmental ← Barclays PLC, bought 3,563,600 shares @ HKD1.70 for HK$6.05M total Read: Barclays now holds just over 10% of this small-cap waste-management H-share, a sizeable new disclosed position.

🆕 NEW ENTRY — 1548 GenScript Biotech ← 483A Bay Street Holdings LP, bought 2,795,289 shares @ HKD41.78 for HK$116.79M total Read: First of seven linked filers (Bay Street/Fidelity/Pandanus chain) jointly crossing 5% in GenScript — a large, coordinated new stake.

🆕 NEW ENTRY — 1548 GenScript Biotech ← 483A Bay Street Holdings Management LLC, bought 2,795,289 shares @ HKD41.78 for HK$116.79M total Read: Same aggregate GenScript position disclosed one rung up the Bay Street ownership chain — no incremental buying beyond the group stake.

🆕 NEW ENTRY — 1548 GenScript Biotech ← Fidelity Canada Investors LLC, bought 2,795,289 shares @ HKD41.78 for HK$116.79M total Read: Fidelity's Canadian entity reports the identical shared 5.1% GenScript stake as its chain affiliates.

🆕 NEW ENTRY — 1548 GenScript Biotech ← FIL Limited, bought 2,795,289 shares @ HKD41.78 for HK$116.79M total Read: FIL Limited (Fidelity International) discloses the same aggregate GenScript stake alongside its fund-complex affiliates.

🆕 NEW ENTRY — 1548 GenScript Biotech ← FMR LLC, bought 6,846,000 shares @ HKD40.25 for HK$275.59M total Read: FMR LLC (Fidelity's US parent) reports a larger, separately-tallied 5.26% GenScript stake a day after its affiliates — the biggest single disclosure in this cluster.

🆕 NEW ENTRY — 1548 GenScript Biotech ← Pandanus Associates Inc., bought 2,795,289 shares @ HKD41.78 for HK$116.79M total Read: Pandanus Associates, the family holding vehicle atop Fidelity, confirms the same shared 5.1% GenScript position.

🆕 NEW ENTRY — 1548 GenScript Biotech ← Pandanus Partners L.P., bought 2,795,289 shares @ HKD41.78 for HK$116.79M total Read: Final leg of the Fidelity/Pandanus chain reporting the same 5.1% new GenScript stake — collectively a meaningful vote of confidence from the Fidelity complex.

🆕 NEW ENTRY — 14 Hysan Development ← BlackRock, 5.05% (increased by 0.13pp from prior filing) Read: A related BlackRock vehicle's holding lapsed while the aggregate group stake rose back above 5% — restructuring, not a new bullish bet on the landlord.

🆕 NEW ENTRY — 1233 Times China Holdings ← JPMorgan Chase & Co., 5.31% (increased by 4.57pp from prior filing) Read: JPMorgan's aggregate stake in the distressed developer jumps sharply as related-entity positions consolidate under one filer — a notable re-concentration worth watching even though it isn't open-market buying.

🆕 NEW ENTRY — 2359 WuXi AppTec ← BlackRock, bought 1,167,015 shares @ HKD179.83 for HK$209.87M total Read: BlackRock crosses 5% in the CRO/CDMO bellwether with a sizeable fresh stake, consistent with broader institutional accumulation in China healthcare names.

🏢 BUYBACK — 1133 Harbin Electric ← BlackRock, 4.48% (decreased by 0.72pp from prior filing) Read: BlackRock's stake mechanically slips below 5% as the issuer's own buyback shrinks the share count — not a BlackRock sell-down.

🏢 BUYBACK — 9927 Seres Group ← BlackRock, 6.19% (decreased by 1.00pp from prior filing) Read: Seres' own share buyback dilutes BlackRock's percentage stake even though its absolute share count is unchanged.

⚙️ OPTION/CONVERSION — 2595 GenFleet Therapeutics ← HL GP II Company Limited, subscribed 6,000,000 new shares @ HKD27.30 for HK$163.80M total Read: Fresh share subscription dilutes existing holders' percentages even as this investor group adds a meaningful new position.

⚙️ OPTION/CONVERSION — 2595 GenFleet Therapeutics ← HL Partners II L.P., subscribed 6,000,000 new shares @ HKD27.30 for HK$163.80M total Read: Same subscription reported up the HL Partners ownership chain — the 4.64% aggregate reflects post-dilution math, not a reduced position.

⚙️ OPTION/CONVERSION — 2595 GenFleet Therapeutics ← Ourea Biotech HK Limited, subscribed 6,000,000 new shares @ HKD27.30 for HK$163.80M total Read: Third leg of the same HL Partners-linked subscription — routine paperwork rather than a separate purchase.

⚙️ OPTION/CONVERSION — 1417 Riverine China Holdings ← Cantrust (Far East) Limited, subscribed 30,000,000 new shares @ HKD3.00 for HK$89.89M total Read: A large subscription lifts Cantrust's absolute holding, yet its 47.63% stake still fell 7.40pp as the deal expanded Riverine's total share base considerably.

🔵 MAINTENANCE

• 1099 Sinopharm Group ← FMR LLC, 3.99% (decreased by 1.79pp from prior filing) Read: Shares shifting within FMR's securities lending pool (L/P bucket reclassification) — a custodial bookkeeping move, not a sale.